Get started

Healthcare

HCAT LongTechnical Analysis : We broke the downtrend line and had three white soldiers to confirm the reversal of the trend, also the falling wedge shows a bullish reversal since we broke it upwards. Although on a lower timeframe MACD and RSI look bearish, we expect the price to reach our Buy Zone before the impulsive move upwards. Aroon : Aroon Up on Top and Aroon Down on bottom show a bullish momentum. MACD : We had lower lows on the chart but not on MACD which shows MACD divergence and signals for a reverse of the downtrend. Entry : 21.5-23.5 Target : 39.75 (at Fib50% and just below a previous high and resistance ) Invalidation : 19.5 ( Just Below our support and last low )
NASDAQ:HCATLong
by vf_investment
BNTX HIGH RISK TO REWARD SETUP YOU CAN'T MISSNews - Better than expected Q4 EPS and sales results, the company expects to authorize a shares repurchase program up to 1.5B over the next two years. Levels -$195 is the next major resistance level. $138 is the next major support level. The stock is gapping up to $183 (pre-market). The idea is to go long at the open when it will try to test the $183 support level and fail, then go long above the 5M bull flag pattern if it will happen.
NASDAQ:BNTXLong
by TradeThePool
Anthem, Inc. $ANTM flashing a VCPAnthem, Inc. is a provider of health insurance in the United States and is ranked 23rd on the Fortune 500. Fundamentals are very strong, it has an average YoY revenue growth of +14% for the las three quarters, and the last two quarters had EPS and Margin growth over the hundreds. IBD is giving NYSE:ANTM a #1 rank in its industry group and a 94 relative strength rating. That is synonymous of good fundamentals accompanied by very good technicals. Relative to the NASDAQ, the index has done three lower lows as NYSE:ANTM has done three higher lows. That is the kind of action a future leader does. Also, if you compare it against its sector AMEX:XLV , is doing way better. For the las 5 weeks, the price has been making a classic VCP with a pivot buy above $472. Today had a bad close but with low volume, that is a good sign. But, as the market is still in a correction, breakouts aren't working very well. Is time to be cautios so, if the breakout happens I'll buy 1/4 of my typical position sizing.
ALong
by dpuleo19
2
Signify Health (NYSE: $SGFY) Boasts $773M Revenue Beats! 👩‍⚕️Signify Health, Inc. operates a healthcare platform that utilizes analytics, technology, and healthcare provider networks in the United States. The company operates in two segments, Home & Community Services and Episodes of Care Services. The Home & Community Services segment offers health evaluations performed within the patient's home or at a healthcare provider facility primarily to Medicare Advantage health plans; diagnostic screening and other ancillary services; and services to address healthcare concerns related to social determinants of health. The Episodes of Care Services segment provides services to enhance the healthcare delivery through developing and managing episodic payment programs in partnership with healthcare providers primarily under the Medicare Bundled Payment for Care Improvement Advanced program with Centers for Medicare and Medicaid Services; and care management services. Its customers include health plans, governments, employers, health systems, and physician groups. The company was founded in 2017 and is headquartered in Dallas, Texas with additional offices in Austin, New York, Norwalk, and Rapid City.
SLong
by Bullishcharts
$TLRY blue dream sniper 👁‍🗨*This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* Today team purchased shares of marijuana company Tilray Brands $TLRY at $6.10 per share. Our take profit is $7 with a stop loss at $5.90. Our Entry: $6.10 Take Profit: $7 Stop Loss: $5.90 If you want to see more, please like and follow us @SimplyShowMeTheMoney
NASDAQ:TLRYLong
by SimplyShowMeTheMoney
3
🤔 Healthcare Potential Booming Company?I have a long list as to why this is good. To just dumb it down, it's getting ready to potentially reverse. Check Kagi, Heikin, Baseline (I don't like the "stick" charts), and the regular candle to see where the original retest point was of the shoulder engulfing seller candle. Price has retested that point across all charts and is showing a complete slow down. Price sat at around 5.96 and below for quite some time due to the support level and is showing signs of major slowdown on the Heikin chart. Try baseline for a clearer version of the slowdown but aside from that, don't use it unless you're double checking your work. Anyways, I'm in. Enjoy if you do, if not thanks for reading. Note* I did not proof read, sending as is.
VLong
by Cordali
3
healthcare is outperforming the broader market (XLV)when an overweight sector corrects with the market volatility is higher in general, but thats why it bounces so much more quickly and outperforms other sectors in the same trend. sector rotation will have a play in healthcare if we find a higher low, and bulls have given themselves room to complete that reversal. we should make a higher low somewhere, even if its closer to the bottom than i anticipate, and continue to rally faster than other parts of the market as stocks benefitting from inflow seeking value accumulates.
AMEX:XLVLong
by cerealtrades
Healthcare is still in a bull market - be longAt the start of 2022, healthcare stocks have gotten killed, especially anything that was a winner in the past 1-2 years. A lot of people are getting rather bearish, but they shouldn't be. The fundamentals favor healthcare still in many ways, and momentum is still rather strong. We already got the breakout in healthcare stocks, and we just got the retest, which was enough to scare a lot of people out. Now is a great entry for a long position, coming out of a short consolidation into a potential new bull phase.
AMEX:XLVLong
by GTStockmaster
$ARKG - Weekly TF AnalysisThe macro count is pretty clear. We're below the 38.2% fib of the impulsive move from the covid lows, and approaching the 50% fib as well as the bottom of the channel. The weekly RSI is lower then even the covid lows of march 2020. In fact the RSI hasn't been this low since inception in 2016. As with all of ARK's ETF's these are long term plays. If you want biotech exposure, this is a great time to buy this ETF. Ask yourself, do you think the healthcare industry is likely to be more profitable over the next 5 years or less profitable? Do you think innovations in gene editing, DNA sequencing and mRNA technology is going to increase or have we peaked in this era of perpetual covid?
CBOE:ARKGLong
by ir-rizzle
Pfizer (PFE) to continue its BULL run in 2022!Fundamental Analysis Pfizer, Inc. has consistently been one of the largest pharmaceutical companies in the world for the better part of the last two decades. The company has a remarkable history going back all the way to the year 1849, when Pfizer was founded in Brooklyn, New York. The large cap pharma giant has developed a well-balanced and deep portfolio of products in key areas like Inflammation and Immunology, Internal Medicine, Oncology, Rare Disease, Vaccines etc. However, it seems that as a result of the success of Pfizer's vaccine COVID-19 treatments, many investors have forgotten about the rest of Pfizer's business and how successful it continues to be. It is true that the sales of its COVID-19 vaccine ($36 billion in 2021 alone) have managed to nearly double Pfizer's annual revenue from $41.9 billion in 2020 to over $78 billion in 2021. What's even more important is that the strong sales growth has also translated into higher profits for the company as its profit margins before interest and taxes, referred to as EBIT margin, have risen over the past year. This shows that Pfizer has managed its R&D and all other fixed and operating costs associated with development, production and distribution efficiently, thus improving the profitability ratios of the company. The large cap pharma giant has also managed to almost triple the size of its free cash flow to more than $29 billion over the past twelve months compared to only $11.6 billion in 2020. More free cash flow makes a business more robust, giving Pfizer more money to invest in research and development of new products, pay more in dividends, or strengthen its balance sheet. The company currently has a total of 94 drugs in the pipeline spread across critical treatment areas like Inflammation and Immunology, Internal Medicine, Oncology, Rare Disease, Vaccines etc. all waiting regulatory approval. - Phase 1(27); Phase 2 (29); Phase 3 (29); Registration (9) Looking at the outstanding track record of Pfizer's drug development capabilities, we can easily state that the company will continue to be a leader in the sector that it operates in. Macro view The equity markets in the US are currently undergoing a process of meaningful repricing and re-valuation of what companies are actually worth, as everyone is getting ready for the Federal Reserve to start raising interest rates in the US and tighten its monetary policy. In a rising interest rate environment, investors tend to move away from expensive high-growth stocks trading at unreasonably high P/E and P/S valuations as the tighter monetary policy environment makes it much more difficult and more expensive for such companies to borrow and invest capital and produce the high earnings growth that investors expect from them. Well-established large cap Healthcare and Biotech stocks are considered to be least correlated with the monetary policy situation in the country as they tend to trade more on FDA drug approvals and drug-related announcements rather than actual earnings per share. Most of the leaders in this space also have a substantial pricing power, as people using their medicines are doing so because they need them and because the drugs are helping them get better. Thus, owning Healthcare and Biotech stocks in a rising inflation and interest rate environment is a defensive play that could end up paying off big time, as stocks in these sectors are rather volatile. Technical Analysis The stock has experienced a volatile retracement from its $61 all-time highs and is currently in a corrective phase. However, the uptrend is still intact as the price is well above both the strong horizontal support at $51 and the upward sloping diagonal support (blue line) at $44. Furthermore, the stock is trading above its 5, 20, 50, 200 EMAs, which is also a bullish continuation signal. We expect buyers to start coming in around the $52-53 level, thus establishing the next higher high. Once that is done, the stock will re-test its ATH at around $61 in Q1 of this year. The broad market framework, together with the many positive company related developments in the coming months are expected to bring enough momentum to the stock in order for it to break its previous ATH and set a new one sometime in Q2. Our target for the stock in H1 of 2022 is around the $68 level, which is roughly 30% higher from the current levels. Follow and Copy us on eToro for more detailed market analyses, profitable trading ideas and a consistent portfolio performance. [ b] Sincerely, @DowExperts
NYSE:PFELong
by DowExperts